Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Kiatichai Faksri

Kiatichai Faksri

Khon Kaen University, Thailand

Title: Whole genome sequence based genotypic-phenotypic comparisons of Mycobacterium tuberculosis causing

Biography

Biography: Kiatichai Faksri

Abstract

Drug resistant tuberculosis (TB) is a major public health problem.  The information regarding genotypic-phenotypic association of anti-TB drugs were limited, especially for the second line drugs. The aim of this study is to compare the concordant rate between whole genome sequence (WGS) based genotypic and phenotypic drug susceptibility testing of Mycobacterium tuberculosis (Mtb) (n = 293). Drug susceptibility test using standard proportional method (agar based test) and whole genome sequencing (WGS) using Illumina platform of Mtb causing drug sensitive (n=51), mono-resistant (n=38), multi-drug resistant (MDR) (n = 96), MDR with fluoroquinolone resistant (n=84) and extensively-drug resistant (n = 23) TB in Thailand during 1998-2016 were performed. WGS analysis was performed using genetic mutation databases from PhyResSE and TB-Profiler program. It was found that the concordant rate between PhyResSE based genotype and phenotype of the first line drugs and second line drugs were 91.4% and 77.8%, respectively. The concordant rate between TB-profiler and phenotype of the first line drugs and second line drugs were 91.96% and 80.65% respectively. We found that particular drug in fluoroquinolone group were not homogeneously concordant to phenotypic results, e.g. Ofloxacin 90.3% vs Gatifloxacin was 56.6%. This study reported that the drug resistance mutation databases, especially for the second line drugs need to be improved. TB-Profiler database provide higher performance for detection of drug resistant TB for both the first and second line drugs. The mutations in gyrA and gyrB were not homogeneously associated to particular drug in fluoroquinolone groups.